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Abstract: The intestinal absorption of fatty acids, glucose and fructose is part of the basic requirements
for the provision of energy in the body. High access of saturated long-chain fatty acids (LCFA), glucose
and fructose can facilitate the development of metabolic diseases, particularly the metabolic syndrome
and type-2 diabetes mellitus (T2DM). Research has been done to find substances which decelerate or
inhibit intestinal resorption of these specific food components. Promising targets are the inhibition
of intestinal long-chain fatty acid (FATP2, FATP4), glucose (SGLT1, GLUT2) and fructose (GLUT2,
GLUT5) transporters by plant extracts and by pure substances. The largest part of active components
in plant extracts belongs to the group of polyphenols. This review summarizes the knowledge about
binding sites of named transporters and lists the plant extracts which were tested in Caco-2 cells
regarding uptake inhibition.
Keywords: diabetes; Caco-2 cells; plant extracts; uptake inhibition; intestinal transporters; FATP2;
FATP4; SGLT1; GLUT2; GLUT5
1. Introduction
As many diseases are triggered by an unhealthy lifestyle, the metabolic syndrome, which is
a preliminary stage of type-2 diabetes mellitus (T2DM), is caused by overweight; obesity; tobacco
consumption; physical inactiveness; and unhealthy nutrition, especially high levels of saturated
long-chain fatty acids (LCFA), glucose and fructose. The metabolic syndrome is accompanied by
impaired glucose tolerance, insulin resistance in peripheral tissues, and raised fasting and postprandial
glucose and insulin levels. The latter leads to an exhaustion of insulin production in the islets of
Langerhans, to dysregulated insulin secretion and to β-cell apoptosis. During the progression of the
disorder, the insulin secretion of the pancreas decreases and the metabolic abnormalities increase and
turn into a manifest T2DM [1,2].
T2DM causes damage to the heart, blood vessels, nerves, eyes and kidneys in a serious way,
which can lead to blindness, limb amputation, heart attack and other endpoints, if not treated
appropriately. Not only high glucose and fructose levels, but also elevated saturated fat levels in the
blood can impair glucose tolerance and fasting glycemia [2].
Civilization-caused diseases spread over the world due to unreasonable lifestyle changes and
a lack of information. In 2014, 422 million people were suffering from T2DM and the number is going
to raise to twice as much in the next 20 years. T2DM makes up approximately 90% of all diabetes forms
worldwide and there is raising incidence for developing the disease in childhood. In 2015, roughly
1.6 million people died of diabetes mellitus [2–5]. Some traditional medicines contain plant extracts
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which are used to improve symptoms or stop the progression of the disease. Therefore, research
has been done to test plant extracts and pure components for their inhibitory activity on intestinal
glucose and fructose transporters using different cell models and detection methods. In contrast, a few
natural extracts and some pure substances have been tested to inhibit saturated LCFA transporters
in the intestine. With regard to the studies which are listed in this review, the active substances in
natural plant extracts mostly belong to polyphenols, such as polyketides (anthocyanins, flavonoids),
phenyl propane derivatives (phenyl acrylic acids, lignins) and tannins (catechin tannins, gallotannins),
which are structurally shown in Figure 1.
Figure 1. The group of polyphenols consists of different subgroups. This figure only shows polyketids,
phenylpropane derivatives and tannins which, in turn, include subgroups. Many of the active
substances in plant extracts are derived from the basic structures, which are shown in the illustration.
The body’s enzymes and intestinal bacteria are able to metabolize some of the active ingredients
because they are often conjugated structures linked to sugars, organic acids or other groups.
Polyphenols are able to inhibit or to retard glucose uptake by interacting with digestive enzymes,
membrane-bound brush border enzymes and apically located transporters [6], as illustrated in Figure 2.
Figure 2. Feasible targets of polyphenols in the intestinal lumen.
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2. The Role of Intestinal Fatty Acid, Glucose and Fructose Uptake with Regards to Developing
Metabolic Disorders
As known, high loads of specific food components such as monosaccharides and fatty acids, play
a crucial role in developing metabolic disorders. Therefore, the suppression or delay of the intestinal
saturated LCFA, glucose and fructose absorption into the enterocytes represents a possible target.
Decelerating digestion of these food components can improve the health status of the patient and
stop the deterioration of the disorder by avoiding high postprandial glucose, fructose and saturated
LCFA peaks in the blood [7–10]. Additionally, the reduction of overweight, which is also related with
permanent increased fatty acid blood concentrations, can abolish the progression of the metabolic
syndrome and T2DM [9]. Metabolic disorders are very complex and affect the health level of the
whole body. Patients with T2DM show an elevated risk to suffer from cardiovascular diseases and
early mortality [1,11].
Studies tried to show the relevance of transporters in different models. The intestinal LCFA uptake of
fatty acid transport protein 2 (FATP2)-knockout mice has not been observed, but selective FATP2 inhibitors,
such as Lipofermata, show 80% attenuation of LCFA uptake across the gut [12,13]. A 48% decrease of
FATP4 protein level leads to a 40% reduction of LCFA uptake in isolated primary enterocytes of mice,
whereas no change of lipid uptake has been detected in vivo. This observation could be related to the
large capacity of the small intestine regarding fat absorption [14]. Röder et al. showed not only a reduced
uptake of glucose into enterocytes in sodium-glucose linked transporter 1 (SGLT1)-lacking mice, but
also lower serum concentration of glucose and a decreased GIP and GLP-1 secretion after ingestion [15].
Glucose transporter 2 (GLUT2) is present in many organs, e.g. liver, β-cells and kidney, which manage
metabolic processes, especially glucose homeostasis. Of course, GLUT2-knockout miceshow sever
damage in their metabolic processes and suffer from early mortality. Surprisingly, intestinal GLUT2
absence appeared not to have any influence on intestinal glucose uptake [16]. This observation could
be related to a compensating effect of SGLT1 as major intestinal glucose transporter. Experiments with
GLUT5 knockout mice showed the relevance of GLUT5 in intestinal fructose uptake. The fructose
absorption was reduced by 75% and the serum level decreased by 90% compared to wild mice after
fructose ingestion [17]. Table 1 shows the tissue expression of these transporters, which might be relevant
when looking for side effects after absorption of inhibitors.
Table 1. Predominant tissue expression of the intestinal LCFA, glucose and fructose transporters.
















2.1. Fatty Acids and Obesity
Fatty acids show multifunctional properties in physiological tissues. They are basic material
for membrane biosynthesis, are crucial for transcriptional regulation and exhibit a central source
for the provision of energy maintaining the metabolic processes in the human body [7]. Excess of
fatty acids leads to accumulation of these food components in non-adipose tissues, such as liver and
muscles, which are not designed to store fat in high amounts. Enrichment of fatty acids, especially of
saturated LCFAs, in non-adipose tissues entails devastating consequences, in particular, endoplasmic
reticulum-stress (ER-stress), and cell dysfunction and apoptosis, designated as lipotoxicity [9,10,12].
With a focus on obesity and nutrition, some food components such as saturated LCFAs and trans-fatty
acids are able to trigger inflammatory activity, which plays also an important role in generating insulin
resistance, starting mainly in hypothalamus before going down to other tissues and organs [1,8–11].
The level of inflammation processes due to the activity of cytokines as well as the serum concentration
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of fatty acids are increased in obese people and can lead to a chronic decrease of insulin secretion by
pancreatic β-cells [7,11,21,22].
Especially palmitate and arachidonic acids trigger ER-stress, cell death and inactivation of
the insulin receptor-signaling cascade due to increased activation of c-jun-N-terminal kinase (JNK)
and inhibition of insulin receptor substrate-1 by a phosphorylation at a critical serine/threonine
residue [8,21,23–25]. ER-stress is suggested to be linked with the activation of sterol regulatory
element-binding protein (SREBP) [7]. Saturated LCFAs initiate a decrease of mitochondrial cardiolipin,
which promotes the release of cytochrome C, one of the protagonists in the process of cell apoptosis.
Furthermore, metabolites of fatty acids are used in the biosynthesis of ceramides, which are known
as lipid signaling molecules and inducers of cell death. Excess of saturated LCFAs, especially
palmitate, influences the cell metabolism negatively by altering many cell cascades and processes
due to reduced phosphorylation of protein kinase B, elevated diacylglycerol levels and protein kinase
C-ε activity, decreased activation of phosphatidylinositol-3-kinase and generally an increased cellular
oxidative stress in different models [11,21,24]. Additionally, saturated LCFAs are able to influence
the expression of glucose transporter 2 (GLUT2) negatively and serve as a substrate of peroxisome
proliferator-activated receptor α (PPARα) modulating insulin secretion [21].
In contrast, polyunsaturated fatty acids appear to have a good impact on the body’s fat
metabolism [23]. Unsaturated fatty acids including mono- and polyunsaturated fatty acids (MUFA,
PUFA), especially omega-3 fatty acids, such as eicosapentaenoic (EPS) and docosoahexaenoic acid
(DHA), but also oleate, act as counterparts to their saturated derivatives and are able to prevent
induced ER-stress, inflammation and insulin resistance [9,10,22,25].
2.2. Monosaccharides and Glycemia
The impact of monosaccharides, especially glucose and fructose, on the development of metabolic
disorders and the exact mechanism are still debated and studies show controversial findings [26,27].
Fructose is a component of sweeteners like sucrose and high fructose corn syrup. It is supposed to be
one of the main actors of dysregulating fat and carbohydrate metabolism, causing insulin resistance,
non-alcoholic fatty liver and hyperuricemia [26]. The liver gathers 70% of oral fructose intake and
15–30% of glucose intake [28,29]. Fructose metabolism promotes and enhances synthesis of lipids in
the liver by providing substrates for lipogenesis and activating SREBP-1c [26–28,30]. Furthermore, it is
suggested that fructose causes hyperinsulinemia, as shown in rats and humans [31,32], and decreased
insulin sensitivity in humans [33,34], but the mechanism remains unclear [28]. The negative effects
of monosaccharides on metabolism depend on the amount of total energy intake [27,30], which is
significant for the accumulation of fat in liver and muscles. Excessive intake of sugars (fructose,
glucose, sucrose) accompanied by other energizing sources as existing in patients with increased serum
lipid levels, leads more easily to an enrichment of fat in the liver and muscles related to obesity and
impaired insulin sensitivity, which generates metabolic disorders [27,30].
Once unhealthy nutrition and lifestyle, including excessive uptake of sugars or saturated LCFAs,
has wreaked damage and insulin resistance, the metabolic processes of glucose are restricted, which is
leading to additional defects supporting the progression of the metabolic disease. At this point,
high blood glucose peaks are even more harmful because they stay for an unphysiologically long
duration due to insulin resistance of the main insulin-dependent glucose transporters in peripheral
tissues [35]. The irreversible non-enzymatic reaction of proteins with reducing sugars such as glucose,
occurs as a product of high unphysiological blood glucose levels for weeks and months. At first,
amino groups of endogenous proteins, lipids and nucleic acids react with glucose to a Schiff base and
Amadori products which are reversible reaction products. Subsequently, they will be modified to
advanced glycosylation end products (AGEs) irreversibly [36], whereby they lose their physiological
functions and they are not able to work appropriately, entailing a slow destruction of tissues and
organs [36,37]. Many typical symptoms of T2DM and comorbidities take shape, e.g. neuropathy,
retinopathy, nephropathy, vascular disease etc. [1,2]. T2DM patients show a two- to three-fold
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increased risk to die of cerebro-cardiovascular diseases and events, such as heart attack or stroke [2],
due to acceleration of atherosclerosis caused by AGE-linked low density lipoprotein (AGE-LDL),
which reattaches to tissues inside and outside the vasculature [38–40]. The AGEs are also used in
diagnosis and therapy control. The glycosylation of hemoglobin type A1c (HbA1c) works as a marker
for diabetic complications to check therapy response and compliance [41]. The postprandial increase
of the blood glucose concentration depends on the food components and can be expressed as glycemic
index. Studies show a preferable effectivity of diets with low glycemic nutrients regarding the control
of glycemia, increase of insulin sensitivity and reduction of glycosylated hemoglobin [1].
3. Cell Models
Apart from experiments on animals such as rats, mice or rabbits or on animal intestinal
tissue compartments, there are existing cell models with human cell lines which are less invasive,
well examined and convenient for studying transport mechanisms. The selection for one of the cell
lines depends mostly on the duration of proliferation; the type of differentiation regarding transporters,
tight junctions and enzymes; specific characteristics of the cell line; availability; or other experimental
requirements for the cells. Thirty years ago, Chantret et al. gave a short summary about some of
the cell lines and classified them into four groups. The first group included only human colonic
adenocarcinoma (Caco-2) cells. They are able to spontaneously differentiate into enterocytes with
features of the small intestine within approximately 20 days after confluence and are, to date, one of
the most used cell lines for transport studies [42–45]. Meanwhile, some companies provide over
60 different human adenocarcinoma cell lines derived from tumors at various stages developing
different characteristics. Caco-2 cells grow into a polarized monolayer with an apical brush border
and brush border-associated hydrolases, such as lactase and alkaline phosphatase [42]. The cell line
also expresses transporters, such as fatty acid transport protein 2 (FATP2), FATP4 [46], sodium-glucose
linked transporter 1 (SGLT1), GLUT2 and GLUT5 [47]. The expression of SGLT1 varies from the cell
bank origin [48]. For exhibiting a homogeneous expression of differentiated traits, clones of Caco-2
cells as e.g. Caco-2/TC7 were cultivated [45]. Cluster determinant 36 (CD36) and fatty acid binding
proteins (FABPs) are also present in the intestine [49,50], but their attendance is not investigated for
Caco-2 cells yet. However, there is not much knowledge about the role and arrangement of CD36
and FABP in intestinal fatty acids transport. For investigations into cell lines, specific inhibitors,
as shown in Table 2, block the activity of transporters whose influence is not intended. It is challenging
to screen plant extracts in the presence of all these transport proteins and to assign the inhibitory
effect to one transporter. Furthermore, differentiation of Caco-2 cells is time-consuming [51]. For this
reason, there are existing methods called cell-high-throughput-screening assay (HTS)-optimizing
substance screenings. Black et al. designed a live-cell high-throughput-screening assay with yeast
cells of Saccharomyces cerevisiae (Desm.) Meyen, 1838 which express Mus musculus Linnaeus fatty acid
protein 2 (mmFATP2) [52]. Although yeast cells proliferate rapidly, they reconstitute the function
of Homo sapiens Linnaeus, 1758 fatty acid transport proteins (hsFATPs) [51]. Zhou et al. created
a HTS with recombinant hsFATP1, hsFATP4 and hsFATP5 expressed in human kidney embryonic
293 (HKE293) cells [51]. A yeast-based screening system with cells of Saccharomyces cerevisiae (Desm.)
Meyen, 1838 expressing hsGLUT5 has been generated to facilitate screening assays for inhibitors [53].
The question remains whether cells of Saccharomyces cerevisiae (Desm.) Meyen, 1838 and HKE cells can
represent the basic character of human enterocytes.
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Table 2. Synthetic and plant-based inhibitors: Specific inhibitors of each of the discussed transporters, which could be suitable for cell line experiments to determine
transport activity in the presence of other transporters.
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4. Transport Mechanisms and Binding Sites of Intestinal Saturated LCFA, Glucose
and Fructose Transporters
The subsequent analysis of the binding sites of LCFA, glucose and fructose transporters plays
a crucial role in understanding the interactions between transporter and inhibitor and in identifying
substances with inhibitory activity.
4.1. Intestinal Long-Chain Fatty Acid Transporters
LCFA (>12 C-atoms) [54] transport can be differentiated into non-protein-mediated and protein-
mediated transit. Passive diffusion of LCFAs mainly occurs at high intestinal concentrations of the un-ionized
substrate, whereas ionized LCFAs and low physiological concentrations of un-ionized LCFAs require
protein-mediated permeation [62]. Three classes of fatty acid transport proteins have been identified:
plasma membrane FABP (FABPpm), fatty acid translocase (FAT = scavenger receptor CD36) and the family
of FATP1-6 [62–64].
Stahl et al. presumed that cluster of differentiation 36 (CD36), FATP, (V)LACS ((very) long-chain
acyl-CoA-synthethase) and FABP, which are shown in Figure 3, are arranged in a complex to result in
more effective transportation of LCFAs through the cell membrane [65,66].
Figure 3. Simplified illustration of the proteins which are involved in fatty acid transport into the enterocyte.
Yet it is not clarified whether a first docking of the LCFA onto cluster of differentiation 36 (CD36) is required
to initiate the transport process. The proteins are working in a complex whereby FATP seems to be the
main actor. The transportation of the LCFA into the cell by FATP is coupled to the vectorial acylation to
start cleavage by very long-chain acyl-CoA-synthetase (VLACS). Acyl-CoA-binding protein (ACBP) and
FABP transport the LCFA-Acyl-CoA and the incorporated LCFA within the cell stimulating a concentration
gradient, which enhances the transport.
Different types of fatty acid transport proteins have different functions and not all of them are
suitable to work as a target for inhibitors of intestinal fat absorption. Primarily, FABP appears to
modulate intracellular lipid homeostasis and therefore substrates are not able to reach it easily from the
extracellular compartment [50,67]. CD36 is a ubiquitous protein with various functions, e.g. facilitating
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LCFA uptake in the heart and adipose tissues in rodents. Noushmehr et al. discussed the role of
CD36 as a modulator of insulin secretion and fatty acids uptake into β-cells [68]. Sulfo-N-succinimidyl
oleate is an irreversible inhibitor of the transport protein [68,69]. Recent studies showed the essential
influence of intestinal CD36 in regulating lipid-mediated satiety [49] and the release of gut peptides [69].
It probably supports intestinal LCFAs uptake.
Many surveys implicate the FATP family as responsible for the main LCFAs uptake into cells [64].
Within the FATP family, six fatty acid transporters have been identified and they belong to the solute carrier
family 27 (SLC27). FATPs are labeled with the prefix that refers to their origin (hs = Homo sapiens Linnaeus,
1758, mm = Mus musculus Linnaeus, 1758 etc.) and a number as the suffix (1–6) [64]. The LCFA transporter
with the highest incidence in the intestinal system is still debated. The most represented opinion supported
FATP4 [62,64,65,70], but since there was no effect of potential inhibitors in vivo, Black et al. proposed FATP2
as a major intestinal LCFA transporter recently [13]. However, the ineffective in vivo studies of FATP4
inhibitors could relate to the inactivation of the inhibitors by the gut microbiome and/or to the large capacity
of the small intestine regarding fat absorption [71].
The crystal structures of the hsFATP1-6 are unknown, but some elements were identified,
especially for hsFATP1. In mammals, the FATP structure is highly conserved. The identity rate
of 92.2% between mmFATP4 and hsFATP4 is higher than between transporters sharing the same
mammalian origin. In humans, the highest orthologous identity of 60.3% exists between hsFATP1
and hsFATP4 [64,72]. Wu et al. showed a hormone-induced translocation of FATP1 by insulin to the
plasma membrane in adipocytes and skeletal muscle cells, whereas the translocation could not be
shown for FATP4 [72].
In contrast to hydrophilic transporters which usually cross the membrane several times to build
a three-dimensional passage for the substrates, the FATP forms at least one transmembrane segment,
but multiple membrane-associated domains. Additionally, Richards et al. showed in mice that
FATP1 exists as a monomer and homodimer [62,73]. The dimerization of FATP1 probably plays
a crucial role in LCFA transport, but it is unclear which conditions have to be complied to form the
dimer [74]. FATP1 crosses the membrane near the N-terminus, which is facing the extracellular side
and directing three integral domains up to amino acid 190. The segment between 191–257 is not
membrane-associated, faces the cytosolic side of the cell and contains 11 amino acids (IYTSGTTGXPK).
This motif is consistent in proteins, which either have an interaction side with ATP or catalyze reactions
such as acyl-CoA-synthetases, proceeding through adenylated intermediates. Residues 258–475 are
located on the peripheral side of the membrane facing the cytosol. The last amino acid sequence
of the C-terminus, which contains amino acids 476–646, is not membrane-associated and is turned
toward the cytosolic side of the cell as well [62,73]. The structure topology of the outer binding pocket
resembles a lipocalin motif, which appears in many transporters with lipophilic substrates [63,75,76].
Many hydrophobic domains are expressed in the segment of the N-terminus that is currently the
only part of the transporter with a predicted α-helical structure and is responsible for the substrate
docking. The binding site for either ATP or adenylated intermediates supports the acceptance of the
subsequent esterification. This vectorial acylation belongs to the transport process of LCFAs and very
long-chain fatty acids (VLCFAs), either as an additional associated unit or as a bifunctional transport
protein [62,65,73,77], which could also be shown for Saccharomyces cerevisiae (Desm.) Meyen, 1838 [78].
VLACS forms fatty acid-CoA derivatives and therefore is able to improve the fatty acid transport
due to stimulation of a concentration gradient [54], as shown in Figure 3. The hypothesis of vectorial
acylation as a requirement for the metabolism of LCFAs was first put forward by Overath et al. 1969,
when they started experiments with Escherichia coli (Migula, 1895), Castellani and Chalmers, 1919 [13].
The exact mechanism of protein-mediated LCFA trafficking into the cell is still not clarified by now.
4.1.1. Fatty Acid Transport Protein 2 (FATP2) Inhibitors
Trials with yeast cells which expressed human FATP2 showed different motifs generating
interactions between inhibitors and FATP2. The inhibitor is suggested to exhibit a notable lipophilic
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part as a long aliphatic hydrocarbon chain (cetrimonium bromide and benzalkonium chloride) or
a tricyclic core. The tricyclic motif can vary and show a phenothiazine element (perphenazine,
perciazine, chlorpromazine, thioridazine, and flufenazine), a cyclobenzaprine with a seven-membered
ring instead of the six-membered ring in the center of the core (clomipramine, methiothepin maleate,
and cyclobenzaprine) or simply an anthralin structure [46]. No study was performed to show the
impact of FATP2 inhibitors on FATP4 performance. FATP2 is also present in the liver and kidney.
Consequently, after absorption, the FATP2 inhibitor can cause hypertriglyceridemia, which has been
observed as a side effect of antipsychotic drugs such as phenothiazine [46]. Black et al. identified
grassofermata as specific and lipofermata as a non-competitive–specific FATP2 inhibitor whose
structures are shown in Table 2 [13,79]. Both show inhibitory effects on LCFA and VLCFA uptake into
pancreatic β-cells, hepatocytes, myocytes and enterocyte. Accordingly, they are preventive against the
accumulation of fatty acids and palmitate acid-induced cell apoptosis [13].
4.1.2. Fatty Acid Transport Protein 4 (FATP4) Inhibitors
FATP4 is supposed to be mainly located in the skin and in the gut. The inhibitory effect of
4-aryl-3,4-dihydro-pyrimidin-2(1H)-ones, whose basic structure is shown in Table 2, is selective for
FATP4 over FATP2 and FATP5. Blackburn et al. showed the impacts of different molecule modifications
by synthesizing derivatives with various residues. The most effective structure appeared to exhibit
a lipophilic ester at position five and a substitution at the para-position, most suitable for NO2 or CF3.
The residues building the ester are preferably unsaturated and long aliphatic chains [54]. Unfortunately,
the inhibitory effect was observed in vitro, but did not appear in vivo [13,54].
4.2. Intestinal Glucose Transporters
The responsible transporters for the intestinal glucose uptake are SGLT1 and GLUT2 [6], whose
characteristics are listed in Table 3 [18,56,80–82].
Table 3. Characteristics of SGLT1 (solute carrier 5 (SLC5) gene family) and GLUT2 (SLC2 gene family).
SGLT1 is the predominant glucose transporter in the intestine and it shows complex functionality.
Whereas SGLT1 appears to be an active cotransporter, which at first requires the binding of two
sodium ions, GLUT2 facilitates the passive diffusion of glucose through the cell membrane. SGLT1
owns a small range of substrate variety and transports only glucose and galactose, whereas GLUT2
transports glucose, galactose, fructose, mannose and glucosamine.
Characteristics of Intestinal
Glucose Transporters SGLT1 GLUT2
Type of transporter Sodium-dependentactive cotransporter
Sodium-independent
passive transporter
Family SLC5 (SLC5A1) SLC2 (SLC2A2)
Substrates Glucose, galactose Glucose, galactose, fructose,mannose, glucosamine
Localization Apical membrane Basolateral/apical membrane
Total length of amino acid sequence 664 amino acids 524 amino acids
Number of transmembrane segments 14 12
Affinity to glucose High (KM = 0.5–2 mM) Low (KM = 17 mM)
Saturation Yes, >10 mM glucose(capacity low) No (capacity high)
SGLT1 is located apically, whereas GLUT2 is situated basolaterally and facilitates glucose and
fructose transport into the blood stream [82]. Experimental results have indicated that SGLT1 is not
the only pathway for glucose into the enterocyte. When the luminal glucose concentration exceeds
a specific level in the gut, GLUT2 is able to move to the apical side of the enterocyte supporting the
uptake of monosaccharides into the cell shown in Figures 4a and 4b [56]. The GLUT2 translocation is
supposed to be dependent on depolarization and Ca2+-entry due to activation of SGLT1 [6,80,83–86].
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Affleck et al. were able to demonstrate the evidence of GLUT2 proteins at the apical membrane of the
enterocytes immunocytochemically [87]. On the other side, studies show normal results after an oral glucose
tolerance test in knockout mice (without GLUT2) and Fanconi Bickel syndrome (FBS) patients (mutation
in GLUT2) and they do not exhibit any differences in glucose absorption to wild type mice or healthy
humans [82], concluding that GLUT2 inhibitors might not be as effective as SGLT1 inhibitors in vivo.
Figure 4. (a) At low luminal glucose concentrations, GLUT2 is located on the basolateral side of the
cells and it facilitates glucose release into the blood. The sodium-potassium adenosine triphosphatase
(Na+/K+ ATPase) maintains the electrochemical gradient, which is required for the appropriate
performance of SGLT1; whereas GLUT2 and GLUT5 work due to the glucose and fructose concentration
gradient respectively. (b) At high luminal glucose concentrations, GLUT2 is trafficking from the
basolateral to the apical side supporting the glucose uptake into the enterocyte.
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4.2.1. Sodium-Glucose Linked Transporter 1 (SGLT1)
The amount of SGLT1 proteins is fourfold upregulated in the gut of patients with T2DM and
the absorption of monosaccharides from the gut is threefold faster compared to healthy people [6].
SGLT1 is an active, sodium-dependent cotransporter of glucose in a stoichiometry of 2:1. Two ions of
sodium, pursued by one molecule of glucose, follow an electrochemical sodium gradient maintained
by the Na+/K+-ATPase, which is located on the basolateral side of the enterocytes, as illustrated in
Figure 4a,b. SGLT1 belongs to the SLC5-family and is expressed in several tissues and organs, e.g. small
intestine, heart, kidney etc. [18]. The proper mechanism of sugar uptake into the cell undergoes at least
six different kinetic states as shown in Figure 5 [88,89]. The principle of Na+/K+-ATPase and GLUT2
function is also shown in Figure 5, whereby GLUT2 shows a simplified performance [53] compared to
SGLT1. The turnover rate (TOR) characterizes the cycle of conformational changes and is defined as
the average number of complete cycles performed by a single cotransporter per second [90].
Figure 5. Visualization of the different conformational states of the transporters SGLT1, GLUT2/GLUT5
and of the Na+/K+-ATPase, which maintains the sodium-electrochemical gradient. At first, sodium
docks onto extracellular binding sites of the transporter to cause a conformational change,
which facilitate fitting of either glucose or galactose as a substrate into the transmembrane binding
site. The outward-occluded binding site turns into an inward-occluded stage. The transporter opens to
the inward site and releases the sodium and the substrate into the cell. The process finishes when the
inward-facing ligand-free conformation turns into the outward-facing ligand-free position. GLUT2
switches between two conformational states, the inward- and outward-facing conformation, which is
called ‘rocker switch’ and is consistent in the major facilitator superfamily.
The precise crystal structure of hsSGLT1 has not been totally solved yet, but for vSGLT,
which is the bacterial homolog from Vibrio parahaemolyticus (Fujino et al., 1951) Sakazaki et al.,
1963 [91,92]. Although the known crystal structures of vSGLT, bacterial leucine transporter (LeuT),
sodium-benzylhydantoin transport protein from Microbacterium liquefaciens (Collins et al., 1983)
Takeuchi and Hatano 1998 (Mhp1) and glycine-betaine transporter from Corynebacterium glutamicum
(Kinoshita et al., 1958) Abe et al., 1967 (BetP) belong to a different gene family, they share the same
core domain which includes transmembrane segments (TM) 1–10, and the same structural fold [93].
The crystal structures of vSGLT and LeuT are used as tentative models in combination with alignments
for structural and modeling investigations of hsSGLT1. Both transporters, hsSGLT1 and vSGLT,
share 32% identity and 75% similarity in their amino acid sequences [82,88]. HsSGLT consists of
Molecules 2018, 23, 2544 12 of 29
a sequence of 664 amino acid residues which are arranged in 14 transmembrane α-helices, termed
TM-1–13, and contain 13 loops [18,89]. The N-terminus as well as the C-terminus face the outside of
the cell [82]. The renumbering of the common model TM-1–13 is based on the crystal structure of the
LeuT family to simplify comparisons between structural family members [82]. The stoichiometry of
sodium/substrate transport is 2:1 for hsSGLT1, LeuT and BetP and 1:1 for vSGLT and Mhp [93]. Intra-
and intermolecular disulfide bonds stabilize the three-dimensional structure of proteins and support
the formation of binding vestibules as existing in hsSGLT1 [94]. The known intramolecular disulfide
bond in hsSGLT1 connects C255 and C511 [95] and, as proposed by Sasseville et al., hsSGLT1 generates
an intermolecular disulfide-bridged homodimer via C355 in its natural tissue [94,96]. In rabbit SGLT,
three intramolecular bonds were investigated, proposing the existence of more linked loops in human
SGLT [94]. The segment between TM12 and TM13 starts at the intracellular part of the membrane,
but a component of the amino sequence was determined to be located extracellularly. Therefore,
experiments of Sasseville et al. confirmed a reentrant in loop 13 [96]. To date, it is not clarified what the
reentrant loop between TM12 and TM13 exactly looks like. The TM12 segment reaches the cytosolic
room and either it crosses the membrane once and enters TM13 from the extracellular side or it crosses
the membrane twice to enter TM13 from the intracellular side [94,96]. M. Raja et al. used the classical
competitive SGLT1 inhibitor phlorizin, whose structure is shown in Table 2, as a model to determine
the binding structures of SGLT1. The high extracellular affinity and low intracellular inhibition activity
of phlorizin, especially of the aglycone which is supposed to interact with the loop between TM12
and TM13, also support the hypothesis of an extracellularly located loop between TM12 and TM13 as
part of the binding pocket for phlorizin as well as for glucose [94,97]. Conversely, many studies have
identified the location of the sodium binding sides in the half of the N-terminus [94]. Another newly
identified substance LX2761, whose structure is shown in Table 2, appears to act as a selective SGLT1
inhibitor in vivo [57].
Sodium-Binding Site
Two sodium-binding sites, Na1 and Na2, are proposed for hsSGLT1. There has been evidence
that the first sodium ion binds to Na2 and the second sodium ion to Na1 [89]. The binding sites are
characterized by chemical groups of the amino acids and by their distances to the sodium-ion, which are
shown in brackets. The subsequent binding distances might be relevant for inhibitors, which target
the sodium-binding sites. Na2 site of hsSGLT1 corresponds with the Na2 site of vSGLT. The carbonyl
oxygens of A76 (<4 Å), I79 (<4 Å), S389 (<4 Å) and S393, the side chain hydroxyl from S392 (5 Å) and
position D204 of the transporter proteins are coordinating with the sodium molecule [88,89]. The Na1
site of LeuT corresponds to the Na1 site of hsSGLT1 and overlaps with the suggested sugar-binding
pocket. In hsSGLT1, the carbonyl oxygen of H83, the aromatic groups of Y290 and W291 are suggested
to coordinate with both sodium and sugar because the bonds are flexible and dynamic, not static. E102
belongs to the sugar-binding site and is involved in the sodium binding with its carboxylate group as
well as the carbonyl oxygen of N78. Binding interactions are also identified between sodium and H83
(2.5 Å), N78 (2.5 Å), E102 (7.5 Å), Y290 (3.3 Å) and W291 (6.3 Å) [89].
Monosaccharide-Binding Site
To date, known coordinating sites for D-glucose are H83, N78, E102, K321, W289, Y290 W291
and Q457 [89]. As described previously, the glucose-binding pocket is partially overlapping with
the Na1 interaction site. Glucose-binding sites are also proposed to be located around helices 10–13.
Experiments with chimeras of SGLT1 and truncated proteins have shown that residues 381–662,
especially amino acids at positions 457, 468 and 499, are crucial for monosaccharide binding. The loop
between 12 and 13 contains not only a binding site for phlorizin, but also for glucose. Studies with
mutants suggest a correlation between amino acids C345, C351, C355 and C361 and the affinity of
D-glucose binding [94]. W289, Y290 and W291 build a formation of aromatic residues, which are
essential by influencing the affinity of glucose binding. Residues H83 and N78 coordinate with O2,
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E102 with O3, W291 with O4, and Q457 with O5/O6 and form a binding pocket for the substrate.
The H-bond between N78, which is also interacting with K321 and Y290, enhances the electrostatic
potential of the aromatic system and influences the interaction of Y290 and glucose positively [88,89].
Phlorizin-Binding Site
Phlorizin, whose structure is shown in Table 2, has been known for its competitive inhibitory
activity on SGLT1 and it has been used in cellular transport studies for decades [55] The substance
interacts with both the phenol- and the glucoside-(sugar) binding site of SGLT1 [98]. Phlorizin is
not used as a drug treatment for inhibition of SGLT1 because the substance is hydrolyzed easily to
phloretin by gut enzymes such as lactase-phlorizin-hydrolase (LPH), which are located in the brush
border membrane (BBM). Consequently, phlorizin shows a short acting time [99]. Additionally, it has
a stronger inhibiting activity on SGLT2 than on SGLT1 and therefore it is the antecedent of the modern
SGLT2 inhibitors, which act mainly in the renal system [97]. The loop between TM12 and TM13,
which is located extracellularly, has relevance for binding the aglycone of the inhibitor phlorizin,
but also contains a binding site for sugar [94,96].
If the aglycone of an inhibitor is coupled to another sugar residue than glucose, the affinity to the
binding site will be reduced [100]. Furthermore, the sugar residue is supposed to be in its β-d-pyranose
form and the OH-groups in position one, two, three or six are required for proper binding. Otherwise
the binding affinity decreases by a factor of five to >200 [82]. Most of the bonds between the transporter
and the aglycone of phlorizin are hydrogen bonds. The 4-OH group of ring B interacts with R602,
whereas the 4-OH group of ring A is coordinated with D611. The 6-OH-group of ring A is organized
with L606–F609 [97] and residues L606–D611 (LFCGLD) are designated as phlorizin-binding domain
(PBD). The β-d-glucoside of phlorizin interacts with the monosaccharide-binding sites of SGLT1.
The 2-OH and/or 3-OH of the glucose moiety coordinates with K321 and E102, 4-OH with F101 and
6-OH with Q457 [97].
4.2.2. Glucose Transporter 2 (GLUT2) Glucose-Binding-Sites
At low intestinal glucose and fructose concentrations, glucose and fructose uptake into the
enterocyte by SGLT1 and GLUT5 respectively on the apical side entails downhill glucose and fructose
transport into the blood by GLUT2 on the basolateral side [101]. As mentioned previously, GLUT2 is
able to move to the apical side to support glucose and fructose uptake at high luminal concentrations,
as shown in Figures 4a and 4b [101–103]. The crystal structure of hsGLUT2 is not identified yet,
but it is proposed to consist of 524 amino acids and to possess 12 transmembrane segments, forming
an aqueous pore [104] with two subunits [105]. The larger subunit is assumed to shape the active
binding site. Coordinating amino acids with glucose are S145, K146, P149, S150, L153, S233, L234, Y266,
D267, T270, N274, R277, L452, C453, and Q455 [105]. Phloretin, whose structure is shown in Table 2,
is widely used in research studies as a relatively specific GLUT2 inhibitor [56,59,60]. Additionally,
the substance is able to impede translocation of GLUT2 [106]. Other potent but not specific inhibitors
of GLUT2 are glipizide, dihydrochalcone, glaucine and phosphatidylcholine [105].
4.3. Intestinal Fructose Transporters
Fructose uptake into cells is insulin-independent [61] and is managed by transport proteins
which facilitate passive diffusion [53]. GLUT2 transports glucose and fructose as listed in Table 3
and was already discussed under 4.2.2. Primarily, GLUT5 transports fructose into the enterocyte at
the apical side, whereas GLUT2 facilitates fructose transport into the blood stream at the basolateral
side of the cell [107,108]. Although GLUT5 belongs to the GLUT family, it appears to be specific for
fructose transport [107].
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4.3.1. Glucose Transporter 2 (GLUT2) Fructose-Binding Sites
Instead of the amino acid sequence of glutamine-leucine-serine (QLS-motif) in high affinity
glucose transporters, such as GLUT1, GLUT3 and GLUT4, the amino acid sequence of histidine-
valine-alanine (HVA-motif) is conserved in fructose transporters, such as GLUT2 and GLUT5 [109–111].
GLUT2 mainly transports fructose in its furanose form [112]. Research has been done to clear the
binding sites of the monosaccharides [113], however it is still not known which exact amino acids of
the transporter are involved [112]. Studies trying to identify binding sites to characterize facilitated
fructose transport in the human body, have proposed that amino acid I306 plays a crucial role in
fructose selectivity for GLUT2 and I321 for GLUT5 [104].
4.3.2. Glucose Transporter 5 (GLUT5)
The crystal structure of hsGLUT5 is not identified yet, but it is supposed to contain 501 amino
acids and 12 transmembrane segments [108]. GLUT5 also performs the ‘rocker switch’ [53] as
mentioned for GLUT2 in Figure 5. Via the identified crystal structures of the mammalian GLUT5
from Rattus norvegicus Berkenhout, 1769 (rGLUT) and Bos taurus Linnaeus, 1758 (bGLUT) [114]
and due to their ~81% sequence identity to hsGLUT5 [114], many investigations started to model
binding sites of hsGLUT5. Tripp et al. suggested an interaction between S72, S76 in TM2 and
F424, L428 and F432 in TM11 forming the substrate-binding cavity. The change of amino acids,
particularly in bulkier residues, can entail repositioning of TM2 and TM11 into the inward facing
conformation [53]. Nomura et al. proposed the essential involvement of TM7 and TM10 in the
formation of a substrate gate, especially between residues Y382 in TM10 and I295 and V292 in TM7 in
the outward-facing conformation [114]. The binding sites of hsGLUT5 and hsGLUT1 are closely related.
Furthermore, human GLUT1 and bovine GLUT5 share only 43% identity, but their crystal structures
of the inward-facing conformation superimpose very well as shown by Nomura et al [114]. Similar
binding residues between hsGLUT1, bGLUT5, rGLUT5 and hsGLUT5 are suggested. In hsGLUT5,
conserved amino acids include I170 (169 in bovine GLUT5), I174 (173), Q167 (166), Q288 (287), Q289
(288), N325 (324) and W420 (419) [108,114]. Especially, tryptophan at position 420 (419 in bGLUT5)
plays a crucial role in substrate specificity [114]. George-Thompson et al. showed ligand specificity
caused by A396 in hsGLUT5 [61]. Other residues lining the substrate cavity in hsGLUT5, but not
conserved in hsGLUT1 and possibly responsible for fructose specificity, are Y32 (31 in bGLUT5), H387
(386), H419 (418), A396 (395) and S392 (391) [108]. Although GLUT7 transports both D-glucose and
D-fructose, it is the closest isoform to GLUT5 [114] and therefore Ebert et al. formed GLUT5–GLUT7
chimera to discover the indispensable amino acids for specific fructose uptake of GLUT5. The research
group showed a decrease of fructose uptake between 30–80% due to the change of amino acids
S41T, L168V, I170V, I174V, V293I, A323V, C331T, A362V, A364L, T368R, A388S, L398V and a decrease
below 30% as a result of the switch of amino acids V36L, Q167E, T171I, Y297N, V326I, A332S, V333A,
V384I, I399R, P409R, G415D, L428F [108]. A consistent characteristic feature of many transporters
in the major facilitator family are salt-bridges between different transmembrane domains. In the
mammalian GLUT5, there are only existing salt-bridges far from the cavity site in the outward-facing
conformation, including interactions between E151 in TM4, R97 in TM3 and R407 in TM11 and
between E400 in TM10, R158 in TM5 and R340 in TM9 [114]. Rubusoside and epicatechingallate show
inhibitory activity for GLUT5 as well as for GLUT1 and other transporters [53]. Potent and specific
GLUT5 inhibitors are N-[4-(methylsulfonyl)-2-nitrophenyl]-1,3-benzodioxol-5-amine (MSNBA) [53]
and astragalin-6-glucoside [61]. Their structures are shown in Table 2.
Rubusoside-Binding Site
Whereas rubusoside (CAS: 64849-39-4), which is a transfructosylated steviol (diterpen) glycoside
and gained from Rubus suavissimus, S. K. Lee inhibited both GLUT1 and GLUT5, astragalin-6-glucoside
from Phytolacca americana L. acts as specific GLUT5 inhibitor and is structurally shown in Table 2 [61].
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George-Thompson et al. identified some of the responsible binding sites of rubusoside in GLUT5 using
a homology model of hsGLUT5, which is based on the crystal structure of GLUT1. Interactions due to
polar contacts include Q288, Q289 in TM7, N325 in TM8 and S392 in TM10. Although many residues
are conserved in GLUT1 and GLUT5, rubusoside docks differently into the cavity of both transporters.
In GLUT5, it appears to dock in a curved conformation ~13 Å long [61].
5. Plant Extracts with Inhibitory Activity on Intestinal LCFA, Glucose and Fructose Transporters
Traditionally used plants whose extracts have shown inhibitory activity on intestinal glucose and
fructose transporters, are listed in Tables 4 and 5. The discussed active substances are polyphenols
and polysaccharides. Research into the inhibitory activity on intestinal saturated LCFA transporters
has been done more for pure substances than for plant extracts. Table 6 shows β-glucan plant extracts
with inhibitory effects on intestinal LCFA transporters. Nearly all investigations of fatty acid transport
inhibition by polyphenolic plant extracts are refering to the reduction of cell uptake into adipose or
muscle tissues. For example, Feng et al. studied the corrective effect of the pollen of Typhae angustifolia
L. extract to the insulin cascade, improving insulin sensitivity in mouse myoblasts [115].
Table 4. In many of the listed studies, plant extracts were tested in different models simultaneously.
This table presents plants which were tested for their inhibiting and downregulating effects on intestinal
glucose transporters in Caco-2 cells. Whenever inhibition or downregulation of glucose transporters
by plant extracts could be observed but the effect was not described precisely, ‘uptake inhibition’ or
‘downregulation’ respectively is placed in the columns. Some plant extracts showed no effects on
intestinal transporters in Caco-2 cells under available conditions marked with ‘None’, but changing
the preparation method can alter the results as shown for Camellia sinensis (L.) Kuntze. ‘Not specified’
means that the information was not mentioned in the study. The discussed active compounds are
primarily referred to the transport inhibition, but also to antidiabetic effects in total.
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Table 5. In some of the listed studies, plant extracts were tested in different models simultaneously.
This table presents plants which were tested for their inhibiting and downregulating effects on intestinal
fructose transporters in Caco-2 cells. Whenever inhibition or downregulation of fructose transporters
by plant extracts could be observed but the effect was not described precisely, ‘uptake inhibition’ or
‘downregulation’ respectively is placed in the columns. ‘Not specified’ means that the information was
not mentioned in the study. The discussed active compounds are primarily referred to the transport
inhibition, but also to antidiabetic effects in total.
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Table 6. Two plant extracts were tested and both showed inhibitory and downregulating activity on
intestinal fatty acid transporters and their proteins when tested in Caco-2 cells. The discussed active
















Avena L. sp. Grains Uptake inhibition Downregulation ofFABP and FATP4 B-glucan [148]
Hordeum L. sp. Grains Uptake inhibition Downregulation ofFABP and FATP4 B-glucan [148]
6. Polyphenols
Polyphenols belong to the secondary plant compounds, because they are not involved in the
primary metabolism of the botanicals. These substances are presumed to have various positive effects
such as antihyperglycemic, antibacterial, antiviral and antiproliferative properties on human health
and therefore they have constituted the focus of many investigations of new or supporting therapy
options for diseases such as cancer and T2DM [149–152].
Referring to the analytical results of the studies listed in Tables 4–6, discussed polyphenols in
plant extracts, which show inhibiting activity on intestinal LCFA and monosaccharide transporters,
are flavonoids, phenyl acrylic acids and tannins as shown in Figure 1. The flavonoids, which are
substantial for the hypoglycemic effects are deduced from the flavan substructure, as are the chalcone
derivates phloretin and phlorizin whose structures are shown in Table 2 [153,154]. The flavonoles
quercetin, fisetin and myricetin act as potent non-competitive inhibitors of GLUT2 expressed in
Xenopus laevis Daudin, 1802 oocytes and decrease glucose and fructose uptake into the cells [155].
Tannins, especially (−)-epigallocatechin gallate, (−)-epigallocatechin and (−)-epicatechin gallate
showed inhibitory activity for both transporters SGLT1 and GLUT2 [156].
The intestinal transporters for LCFAs, glucose and fructose are not only located in the intestinal
cells, but also in many other human tissues (e.g. GLUT2 in pancreatic β-cells) as listed in Table 1.
Therefore, the interacting mechanism could be transferable in some cases, which can help to predict
the side effects of absorbable polyphenols. After absorption, gallated catechins from green tea such as
epigallocatechin-3-gallate are able to block the glucose uptake into peripheral cells in vivo and can
evoke secondary hyperinsulinemia [157,158].
7. Intestinal Metabolism of Polyphenols
The metabolism and modification of polyphenols, especially of flavonoids, after ingestion, include
the activity of digestive enzymes and gut microbiota. These processes are complex and it is challenging
to ascertain the active structures and interacting targets in the body. The genetic polymorphism
of digestion enzymes and the individuality of gut microbiota play an important role transferring
in vitro data into in vivo data [159,160]. Gut enzymes, which influence the absorption of polyphenols,
are LPH and cytosolic β-glucosidase (CBG) [100,161]. Flavonoids mostly appear as glucosides
before being hydrolyzed enzymatically or non-enzymatically in the gut [100]. LPH is located on
the luminal side of the enterocytes and hydrolyzes flavonoid-O-β-d-glucosides whose aglycones
can easily pass the membrane by passive diffusion. The CBG is located within the enterocytes.
The polar flavonoid glucoside has to be transported into the cell before it can be hydrolyzed by
CBG [100,160,161]. At least two more β-glucosidases, termed glucocerebrosidase and pyridoxine
glucoside hydrolase, exist intracellularly [162]. In experiments, the transport of quercetin-glucosides
into the enterocytes and blood stream appeared to be faster than of quercetin-aglycones. It is suggested
that the glucoside is enabled due to the glucose moiety to act as a substrate of SGLT1 [163,164].
Tsuchihashi et al. investigated the impact of different strains of human microbiota on the intestinal
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metabolism of flavonoids. Most of the strains performed the hydrolysis of the glucosides to the
aglycones except for the aerobe bacteria strains. Some of the bacteria strains appear to catalyze
hydrolysis of specific flavonoids rather than others [165]. The main absorption process is located
in the small intestine and there is not as much gut bacteria as at lower sections of the gut.
Although the impact of microbiota to cleavage of food components is not as big at this point,
Schantz et al. showed that the catechin tannins were cleaved by gut microbiota in human ileal fluids.
(−)-Epigallocatechin-3-O-gallate (EGCG) was metabolized to (−)-epicatechin-3-O-gallate (EGC) and
gallic acid (GA), EGC to 3’,4’,5’-trihydroxyphenyl-γ-valerolactone and ECG to epicatechin and GA
after incubation [166]. Esters of phenyl acrylic acids such as chlorogenic acid are hydrolyzed due to
esterase activity of colon microbiota at lower sections of the gut [167,168].
8. Conclusions
The inhibition of intestinal LCFA, glucose and fructose transporters is a promising target regarding
the prevention and treatment of not only metabolic disorders such as T2DM, but also other diseases
which are correlated with high blood concentration of these food components. Traditionally, used
plants are very suitable as raw starting material for detecting and identifying new active substances.
The plant extract studies, which are listed in Tables 4–6, show that not only polyphenols, but also
polysaccharids are able to act as intestinal uptake inhibitors of LCFA, glucose and fructose. The analysis
of binding sites of relevant intestinal transporters and their interactions with prominent inhibitors
is a crucial step in understanding the transport mechanisms and in identifying selective inhibitors.
In contrast to intestinal glucose transporters, the binding sites of LCFA and fructose transporters are
not as well characterized and examined. Additionally, research has to be done to test more plant
extracts for their inhibitory activity on intestinal LCFA and fructose transporters.
Generally, the inhibition of LCFA, glucose and fructose uptake in the intestine causes higher
luminal concentrations of these nutrients at lower sections of the gut, which can have different impacts.
On the one hand, it can activate the ileal break, which reports to the brain the signal of enough food
intake and decreases appetite [169]. On the other hand, unusual osmotic conditions due to unabsorbed
monosaccharides and fatty acids and cleavage of these food compounds by enterobacteria can lead to
side effects such as flatulence and gripes [170,171]. It is an approach to find uptake inhibitors which
leads to a delay of saturated LCFA, glucose and fructose absorption instead of total inhibition. In this
case, the ileal break is activated, food intake is decreased and at the same time side effects are reduced
compared to total uptake inhibition.
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